ClinicalTrials.Veeva

Menu

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

R

Radiation Therapy Oncology Group

Status and phase

Completed
Phase 3

Conditions

Metastatic Cancer
Breast Cancer
Prostate Cancer
Pain

Treatments

Procedure: pain therapy
Radiation: radiation therapy

Study type

Interventional

Funder types

NETWORK
NIH

Identifiers

NCT00003162
RTOG-9714
NCI-P97-0124
NCCTG-R9714
CDR0000065957

Details and patient eligibility

About

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective for bone metastases.

PURPOSE: Randomized phase III trial to compare different radiation therapy regimens in treating patients who have bone metastases from breast or prostate cancer.

Full description

OBJECTIVES:

  • Compare the ability of a single fraction of radiation therapy vs multiple fractions to provide complete pain relief in patients with painful bone metastases from breast or prostate cancer.
  • Determine the frequency and duration of pain relief and narcotic relief after these treatments in these patient populations.
  • Compare the effect on quality of life of these two treatments in these patient populations.
  • Compare the incidence of pathologic fracture within the treatment fields after these two treatments in these patient populations.

OUTLINE: This is a randomized study.

Patients are assigned to 1 of 2 treatment arms. Arm I consists of radiation therapy delivered in 10 fractions over 2 weeks. Arm II consists of a single dose of radiation therapy. Any retreatment does not occur until at least 4 weeks after prior treatment unless there is an increase of 2 points on the pain score.

Patients are followed and quality of life is assessed at 2 and 4 weeks, then at 2, 3, 6, 9, and 12 months, every 6 months for the next 3 years, then annually until death.

PROJECTED ACCRUAL: This study will accrue 938 patients within 2 years.

Enrollment

949 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

  • Histologically proven breast or prostate cancer

  • Radiographic evidence of bone metastasis within 8 weeks of study

  • Eligible treatment sites:

    • Weight-bearing sites:

      • Pelvis (excluding pubis)
      • Femur
      • Sacrum and/or sacroiliac joints
      • Tibia
    • Non-weight-bearing sites:

      • Up to 5 consecutive cervical, thoracic, or lumbar vertebral bodies
      • Lumbosacral spine
      • Up to 3 consecutive ribs
      • Humerus
      • Fibula
      • Radius with/without ulna
      • Clavicle
      • Scapula
      • Pubis
    • If multiple sites are treated, site is included as weight bearing if any of the sites include the pelvis, sacrum, femur, or tibia

  • Worst pain score of at least 5 on a scale of 10

  • No skull, feet, or hand metastases

  • No spinal cord or cauda equina compression/effacement in vertebral metastases

  • Multiple sites eligible if they can be included in no greater than 3 treatment sites

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 40-100%

Life expectancy:

  • At least 3 months

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • No impending fracture of the treatment site
  • No hematologic primary malignancies
  • Negative pregnancy test

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No change in immunotherapy within 30 days

Chemotherapy:

  • No change in chemotherapy within 30 days

Endocrine therapy:

  • No change in hormonal therapy within 30 days

Radiotherapy:

  • No prior radiation therapy to treatment area
  • At least 30 days since systemic radiotherapy (Sr 89)

Surgery:

  • No prior palliative surgery to treatment area
  • No planned surgical fixation of the bone

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

949 participants in 2 patient groups

3.0 Gy x 10 fractions in two weeks
Active Comparator group
Description:
3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
Treatment:
Procedure: pain therapy
Radiation: radiation therapy
8.0 Gy x 1 fraction
Experimental group
Description:
8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
Treatment:
Procedure: pain therapy
Radiation: radiation therapy

Trial contacts and locations

253

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems